© 2022 MJH Life Sciences™ and Ophthalmology Times. All rights reserved.
December 05, 2022
According to researchers, cells within retinal blood vessels are endowed with a previously unappreciated ability to acquire resistance against the damaging effects of hyperglycemia in patients with diabetes mellitus.
December 04, 2022
SPVN06 is a breakthrough gene therapy approach aimed at stopping or slowing disease progression in patients affected by IRDs and dry age-related macular degeneration (AMD), regardless of their genetic background.
December 03, 2022
Weigh in on this month's survey question. The poll will be open until December 16, 2022.
December 03, 2022
OPGx-001 is Opus’ first program to enter clinical evaluation and is designed to address vision loss due to mutations in the LCA5 gene, which causes one of the most severe forms of early-onset blinding disease Leber congenital amaurosis.
December 03, 2022
In an effort to educate the public on GA, Prevent Blindness has created a variety of resources for patients in English and Spanish.
December 02, 2022
Aflibercept and bevacizumab are the two most frequently used therapies for the treatment of wet AMD.
December 02, 2022
According to the company, the facility will serve as a hub of the EVO Lens-Based Experience for ophthalmic surgeons, staff and healthcare practitioners.
December 02, 2022
December 02, 2022
Discovery CORE and its AI models have been designed to accelerate data analysis and help clinical and academic researchers collaborate more efficiently in real time with their peers on medical and imaging datasets.
December 02, 2022
In a two-decade career as a researcher at Johnson & Johnson Surgical Vision, Piers has been a part of teams at the forefront of a number of innovations in IOLs. She discusses her career and the outlook for research and development in ophthalmology.